Trial Profile
Unrelated reduced intensity conditioning with Treosulfan for allogeneic stem cell transplantation in patients with hematological malignancies.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Treosulfan (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- Acronyms MiniMUD
- 03 Dec 2005 New trial record.